Depolymerized Pectin Composition for Galectin-Targeted Anti-Fibrosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for modified pectins that can be used as medicinal compounds to inhibit inflammation and fibrosis while remaining non-toxic to other cells and tissues, and to target galectin proteins involved in human diseases such as inflammation, fibrosis, and cancer.
Innovation Solution
A selectively depolymerized arabinogalacto-rhamnogalacturonan compound, characterized by specific molecular composition and structure, is developed for parenteral or enteral administration, capable of reducing TNF-alpha cytokine secretion and galectin-3 expression, and is non-cytotoxic to cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If modified pectins are used to inhibit inflammation and fibrosis, then therapeutic effect is improved, but cytotoxicity to cells and tissues may increase
Solution Approach 1:
The patent applies parameter changes by precisely controlling the molecular weight distribution (average molecular weight of 2,000 to 80,000 Daltons) and compositional parameters (molar percentages of different sugar residues) of the polysaccharide compound. This selective depolymerization process modifies the physical and chemical parameters of pectin to achieve optimal therapeutic effect while reducing cytotoxicity, resolving the contradiction between efficacy and safety
Solution Approach 2:
The patent implements local quality by creating specific structural regions within the polysaccharide molecule - a backbone of 1,4-linked GalA and MeGalA residues with specific side chains of 1,4-β-D-galactose and 1,5-α-L-arabinose. This localized structural differentiation allows different parts of the molecule to perform specific functions: the backbone provides structural integrity while the side chains interact with galectin proteins, achieving therapeutic effect without excessive cytotoxicity
2Adaptability or versatility
If pectins are modified for parenteral or enteral administration, then medicinal utility is improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the complex pectin molecule into distinct structural segments with specific functions: the backbone segment (1,4-linked GalA and MeGalA) and the side chain segments (1,4-β-D-galactose and 1,5-α-L-arabinose). This segmentation allows for controlled depolymerization and purification processes that can be standardized for manufacturing, reducing complexity while maintaining medicinal utility for parenteral and enteral administration
3Reliability
If polysaccharide structure is optimized to target galectin proteins, then anti-cancer effect is improved, but selectivity and precision of manufacturing decrease
Solution Approach 1:
The patent implements feedback by using gas chromatography/mass spectrometry to precisely characterize the polysaccharide structure (molar percentages of different residues, molecular weight distribution) and using this information to optimize the depolymerization process. This feedback loop ensures consistent manufacturing precision while maintaining the specific structural features needed to target galectin proteins and achieve anti-cancer effects
Data Source
AI summary
Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-a-L-arabinose (Ara) residues.